Tag: date

MIAMI, July 09, 2025 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or “the Company”) is today reporting on reaching key operational milestones for Le Mans Ultimate, the official game of the FIA World Endurance Championship and the 24 Hours of Le Mans, and RaceControl, the Company’s matchmaking and online racing system, which provides enhanced access to online features, including championships, extended registration periods, and priority driver reports.

Daix (France), New York City (New York, United States), July 9, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced a leadership transition with the appointment of Jason Campagna, MD, PhD, as President of Research and Development (“R&D”) and Chief Medical Officer (“CMO”) and Martine Zimmermann, PharmD, as Executive Vice President (“EVP”) of Regulatory Affairs and Quality Assurance.

Daix (France), New York City (New York, États-Unis), le 9 juillet 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd'hui une transition au sein de son équipe de direction avec la nomination de Jason Campagna, MD, PhD, en tant que Président de la Recherche et du Développement (« R&D ») et Directeur Médical (« CMO »), ainsi que Martine Zimmermann, PharmD, en tant que Vice-Présidente Exécutive (« EVP ») en charge des affaires réglementaires et de l’ assurance qualité.

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 32,350 shares of the Company’s common stock to two new employees (the “Inducement Grants”) on July 2, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).

DANBURY, CT, July 09, 2025 (GLOBE NEWSWIRE) -- Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD) announced today that it will release its financial and operating results for the fiscal 2025 fourth quarter and full year ended June 30, 2025, after the stock market closes on Wednesday, July 30, 2025.

Data from Orbit and Cosmic studies expected around the end of the year

Total number of shares and voting rights in the share capital as of June 30, 2025 
(Articles L. 233-8 (II) of the French Commercial Code and 223-16 of the General Regulations of the French Financial Markets Authority) 

Nombre total de droits de vote et d’actions composant le capital en date du 30 juin 2025
(Art. L. 233-8 (II) du Code de Commerce et Art. 223-16 du Règlement Général de l’AMF)